Add to ORKGObjective: A new 3-month depot formulation of 11.25 mg leuprorelin, has been developed recently. The aim of this study was to evaluate the therapeutic bioequivalence of this new formulation compared with that currently used of 3.75 mg leuprorelin 1-month depot for the treatment of central precocious puberty (CPP). Patients and methods: 18 children (17F, 1M) affected by CPP, with onset of pubertal development before the age of 8 yrs in girls and 9 in boys, were included in the trial. At the time of the inclusion the patients were under treatment with montly depot 3.75 mg leuprorelin for 3- 12 months and showed an adequate gonadotropin suppression (peak LH <3IU/L after GnRH test). Seven patients were randomly selected for continuing...
none7Background. The GnRH agonists are the drugs of choice for therapy of CPP. We report on pituitar...
*Members are listed in the acknowledgements section Objective: Depot GnRH agonists are commonly used...
Background: Precocious puberty may reduce final adult height, and affected children may suffer socia...
Objective: A new 3-month depot formulation of 11.25 mg leuprorelin, has been developed recently. Th...
Objective. A 3-month depot of leuprorelin acetate (LA) was introduced in China in July 2020. However...
Background: In central precocious puberty (CPP), the pulse secretion and release of gonadotropin-rel...
PurposeWe evaluated the efficacy, safety and psychological aspect of monthly administrations of the ...
none12Background: Depot GnRH analogs represent the treatment of choice for central precocious pubert...
Objective. GnRH analogues (GnRHa) are used in the treatment of central precocious puberty (CPP). The...
Background. Depot GnRH analogs represent the treatment of choice for central precocious puberty (CPP...
Copyright © 2015 H. Nur Peltek Kendirci et al. This is an open access article distributed under the ...
Purpose Gonadotropin-releasing hormone agonist (GnRHa) has been the mainstay of central precocious p...
Purpose There are no definite guidelines on the optimal dosage of gonadotropin-releasing hormone (Gn...
BACKGROUND: Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...
Background. Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...
none7Background. The GnRH agonists are the drugs of choice for therapy of CPP. We report on pituitar...
*Members are listed in the acknowledgements section Objective: Depot GnRH agonists are commonly used...
Background: Precocious puberty may reduce final adult height, and affected children may suffer socia...
Objective: A new 3-month depot formulation of 11.25 mg leuprorelin, has been developed recently. Th...
Objective. A 3-month depot of leuprorelin acetate (LA) was introduced in China in July 2020. However...
Background: In central precocious puberty (CPP), the pulse secretion and release of gonadotropin-rel...
PurposeWe evaluated the efficacy, safety and psychological aspect of monthly administrations of the ...
none12Background: Depot GnRH analogs represent the treatment of choice for central precocious pubert...
Objective. GnRH analogues (GnRHa) are used in the treatment of central precocious puberty (CPP). The...
Background. Depot GnRH analogs represent the treatment of choice for central precocious puberty (CPP...
Copyright © 2015 H. Nur Peltek Kendirci et al. This is an open access article distributed under the ...
Purpose Gonadotropin-releasing hormone agonist (GnRHa) has been the mainstay of central precocious p...
Purpose There are no definite guidelines on the optimal dosage of gonadotropin-releasing hormone (Gn...
BACKGROUND: Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...
Background. Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious...
none7Background. The GnRH agonists are the drugs of choice for therapy of CPP. We report on pituitar...
*Members are listed in the acknowledgements section Objective: Depot GnRH agonists are commonly used...
Background: Precocious puberty may reduce final adult height, and affected children may suffer socia...